BSEKabra Drugs LtdMediumNeutral
Announced Mon, 9 Jun · 11:30 IST

Kabra Drugs Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 18/06/2025 ,inter alia, to consider and approve This is to inform you that a meeting ....

Listed Co AcquisitionStrategic Transactions View source PDF

Price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reaction · full curve

Awaiting price reaction for this filing.

AI summary

Kabra Drugs Ltd has informed BSE that its Board of Directors will meet on Wednesday, June 18, 2025 at 5:00 PM at the company's Chennai office. The key agenda items include considering a new acquisition, obtaining a new drug license for the Chennai office, and diversification by creating a new subsidiary. Any other business items may also be taken up with the chair's permission. The company has not disclosed further details on the size or target of the proposed acquisition or the nature of the new subsidiary.

Likely market impact

This is a forward-looking intimation with no confirmed action yet, so the immediate stock impact is limited. If the board approves the acquisition and subsidiary creation on June 18, it could signal a growth and expansion push, potentially driving positive sentiment among shareholders.